Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection or vaccination
Roche has announced the launch of the Elecsys IGRA SARS-CoV-2 test in countries that accept the CE Mark. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection and vaccination. The test will be an additional tool to make better-informed decisions around care, sanitary measures and treatment options. This will be particularly important for at-risk patient groups.
SARS-CoV-2 infection, as well as COVID-19 vaccination, induce both T and B cell responses, in people with a normally functioning immune system, and a timely and well-coordinated T and B cell response is likely the key in infection control. While antibody testing has been adopted to measure antibody-mediated immunity, there is increasing evidence that measuring the complementary T-cell response may play an important role in determining the overall protection level achieved. The Elecsys IGRA SARS-CoV-2 test is intended as an aid in identifying individuals with an adaptive T-cell response to SARS-CoV-2, which is indicative of past exposure to the virus or COVID-19 vaccination.
Thomas Schinecker, CEO, Roche Diagnostics said, “The Elecsys IGRA SARS-CoV-2 test can provide a deeper understanding into immune response. This in turn may help to understand and identify those at higher risk of progressing to severe disease during an existing or future infection. This is particularly important in immunocompromised and high-risk patient groups that represent up to 20 per cent in a given population. The test results can help healthcare professionals to provide them with long-term guidance like appropriate treatment.”